An Overview of the Role of Statins to Inhibit HMG-CoA Activity Reductase.
One group of drugs known for their effectiveness in treating dyslipidemia (a condition that causes high plasma lipid levels) is the statins. Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is responsible for the biosynthesis of cholesterol in the liver. Statins inhibit the enzyme’s activity, reducing the production and secretion of cholesterol in the blood. This results in a decrease of plasma cholesterol. Statin therapy has been studied in numerous studies to determine its safety and effectiveness for treating dyslipidemia. A systematic review of controlled trials that were published in 2020 showed that statin therapy had a significant effect on total cholesterol and low-density cholesterol levels in dyslipidemia patients (Kumar and co-authors, 2020). In 2018, a systematic review and meta-analysis of observational research concluded that long-term statin treatment was associated with lower rates of stroke, cardiovascular disease, and all-cause death (Wang, et al. 2018). Statins are effective in decreasing cholesterol and improving cardiovascular disease prevention. Cont…
Order an Essay Now & Get These Features For Free:
Turnitin Report
Formatting
Title Page
Citation
Outline
